Study Title and Description
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.
Key Questions Addressed
|2||Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?|
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.|
|Author||Grady D., Ettinger B., Moscarelli E., Plouffe L., Sarkar S., Ciaccia A., Cummings S.|
|Country||University of California-San Francisco, 1634 Divisadero Street, Suite 600, San Francisco, CA 94115, USA. email@example.com|
Pubmed ID: 15458908
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.